IMGO's logo.
Ticker Symbol: IMGO

Imago BioSciences Inc

$22.20 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001623715

Company Profile

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: December 31, 1969 07:00 PM EST
Previous Close: -
Change: $0.01 ( 0.03%)
Days Range: $36.01 - $36.01
Beta: -
52wk. High: -
52wk. Low: -
Ytd. Change 0.03%
50 Day Moving Average: -
200 Day Moving Average: -
Shares Outstanding: 33822201

Valuation

Market Cap: 121.8B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A